All Updates

All Updates

icon
Filter
Partnerships
Pluristyx and Humacyte enter partnership to develop treatments for insulin-dependant and type 1 diabetes
Human Gene Editing
Jul 9, 2024
Last week:
Product updates
Eve Air Mobility unveils unmanned eVTOL prototype
Passenger eVTOL Aircraft
Yesterday
Product updates
Lilium advances POWER-ON, providing solutions with leading digital innovators
Passenger eVTOL Aircraft
Yesterday
Industry news
New South Korean space agency provides rundown of plans
Space Travel and Exploration Tech
Jul 20, 2024
Regulation/policy
Airwallex secures license to expand retail investment offerings in Australia
FinTech Infrastructure
Jul 19, 2024
Partnerships
EHang collaborates with KC Smart Mobility to expand EH216-S sales and operations in China
Passenger eVTOL Aircraft
Jul 19, 2024
Industry news
China launches Gaofen-11 high-resolution intelligence satellite
Satellite Management
Jul 19, 2024
Industry news
France funds miniature satellite capture and inspection mission
Satellite Management
Jul 19, 2024
Funding
Partnerships
MyFloraDNA launches crowdfunding campaign to address peanut allergies using CRISPR technology
Crop Biotech
Jul 19, 2024
Partnerships
Ecobloom Technologies partners with Harvest Today to enhance global farming practices
Smart Farming
Jul 19, 2024
Funding
Hyzon Motors announces registered direct offering to raise USD 4.5 million
Truck Industry Tech
Jul 19, 2024
Human Gene Editing

Human Gene Editing

Jul 9, 2024

Pluristyx and Humacyte enter partnership to develop treatments for insulin-dependant and type 1 diabetes

Partnerships

  • Cell therapy technology provider Pluristyx and biotechnology company Humacyte have entered an agreement to develop advanced cellular treatments for type 1 diabetes.

  • According to the agreement, Humacyte has been granted rights to use Pluristyx’s PluriBank cell lines in its BioVascular Pancreas development program. The program aims to combine Humacyte’s Acellular Tissue Engineered Vessel (ATEV) with insulin-producing cells derived from Pluristyx’s best-in-class iPSC lines to create a potential cure for insulin-dependent diabetes and for the treatment of type 1 diabetes.

  • Pluristyx is a biotechnology company that advances cellular therapies through innovative tools and technologies. The company specializes in providing induced pluripotent stem cells (iPSCs) and related expertise to accelerate the development and commercialization of cellular therapeutics. It offers a range of products and services, including the proprietary PluriFreeze cryopreservation media, clinical-grade iPSCs, and the panCELLa platform, which includes technologies such as the FailSafe safety switch and iACT Stealth Cells for immune evasion, to increase the efficiency of the development process.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.